Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at HC Wainwright

Sagimet Biosciences (NASDAQ:SGMT)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $29.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 226.03% from the stock’s current price. HC Wainwright also issued estimates for Sagimet Biosciences’ Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $2.28 EPS.

A number of other equities research analysts have also commented on SGMT. Citigroup reiterated a “market outperform” rating on shares of Sagimet Biosciences in a research report on Thursday, October 1st. Oppenheimer raised their price objective on Sagimet Biosciences from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, October 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Guggenheim raised their price target on shares of Sagimet Biosciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

Sagimet Biosciences Trading Up 1.5%

NASDAQ:SGMT traded up $0.14 during mid-day trading on Monday, hitting $8.90. 383,647 shares of the company’s stock were exchanged, compared to its average volume of 1,196,121. Sagimet Biosciences has a fifty-two week low of $4.50 and a fifty-two week high of $11.45. The company has a 50 day simple moving average of $9.89 and a 200-day simple moving average of $7.83. The firm has a market capitalization of $552.91 million, a P/E ratio of -6.96 and a beta of 3.46.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). As a group, analysts expect that Sagimet Biosciences will post -1.17 earnings per share for the current year.

Insiders Place Their Bets

In other Sagimet Biosciences news, CEO David Happel sold 64,051 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $497,035.76. Following the transaction, the chief executive officer directly owned 741,570 shares of the company’s stock, valued at approximately $5,754,583.20. The trade was a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Elizabeth Rozek sold 10,545 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $81,829.20. Following the transaction, the insider owned 224,414 shares in the company, valued at $1,741,452.64. The trade was a 4.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 113,646 shares of company stock worth $920,491. 11.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sagimet Biosciences

Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Sagimet Biosciences by 82.6% during the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock worth $3,268,000 after buying an additional 282,969 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Sagimet Biosciences in the 2nd quarter worth $3,119,000. Dimensional Fund Advisors LP lifted its holdings in shares of Sagimet Biosciences by 99.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock worth $1,415,000 after purchasing an additional 135,178 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Sagimet Biosciences in the 2nd quarter valued at $1,551,000. Finally, AWM Investment Company Inc. bought a new stake in Sagimet Biosciences during the 2nd quarter valued at $618,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

More Sagimet Biosciences News

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright improved its Q4 2026 EPS estimate to a loss of $0.27 from $0.32 and raised its FY2026 forecast to a loss of $1.31 from $1.48. The revisions suggest lower expected losses and may be helping SGMT trade higher. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: The analyst also raised its EPS estimates for FY2027 to a loss of $1.03 from $1.22 and FY2028 to a loss of $0.64 from $0.85. Longer-term forecasts call for Sagimet to become profitable, with projected EPS of $0.89 in FY2029. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings
• Neutral Sentiment: HC Wainwright slightly reduced its FY2030 EPS forecast to $2.28 from $2.34. Although the estimate remains profitable, the cut signals some uncertainty around the pace or scale of Sagimet’s long-term earnings growth.

Sagimet Biosciences Company Profile

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.